Physician profile
Rajesh Singh
NPI 1710933684
$392,959.06
in general payments reported to CMS, 2019-2025
31 companies · $104K in 2025
The $104K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $22K · 2021: $25K · 2022: $38K · 2023: $39K · 2024: $122K · 2025: $104K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $211K · Consulting Fee: $25K · Travel and Lodging: $22K · Food and Beverage: $7,790 · Education: $316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $210,700.00 |
| Consulting Fee | $25,055.00 |
| Travel and Lodging | $21,600.97 |
| Food and Beverage | $7,789.54 |
| Education | $315.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $122,608.29 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $96,333.61 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $96,073.35 | 2019-2025 | Lybalvi, Aristada |
| Sunovion Pharmaceuticals INC. | $61,741.02 | 2019-2022 | |
| Eisai INC. | $9,230.27 | 2020-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $3,008.75 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $899.88 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $609.15 | 2021-2024 | Qelbree, Qelbree |
| Tris Pharma INC | $383.31 | 2023-2024 | Dyanavel Xr, Quillivant, Quillichew Er |
| Lundbeck LLC | $331.70 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $282.81 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $163.33 | 2020-2022 | |
| Vertical Pharmaceuticals, LLC | $134.05 | 2019-2020 | |
| Shire North American Group INC | $129.37 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $119.74 | 2019-2025 | Trintellix |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $107.84 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $105.17 | 2020-2025 | Fanapt |
| Corium, LLC | $103.73 | 2023-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $81.97 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $76.98 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $73.17 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $69.45 | 2020-2025 | |
| Harmony Biosciences LLC | $50.28 | 2022 | |
| Axsome Therapeutics, INC. | $47.23 | 2022-2023 | Auvelity |
| Neuronetics, INC. | $40.63 | 2019 | |
| Idorsia Pharmaceuticals US INC | $39.57 | 2022-2023 | Quviviq |
| Abbvie INC. | $32.10 | 2021 | |
| Almatica Pharma LLC | $28.44 | 2022-2024 | Loreev Xr |
| Bausch Health US, LLC | $22.51 | 2022 | |
| Biogen, INC. | $19.33 | 2021 | |
| Adlon Therapeutics L.P. | $12.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.